Lipum AB (OSTO:LIPUM) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Days Payable?

Lipum AB's average Accounts Payable for the three months ended in Dec. 2024 was kr5.80 Mil. Lipum AB's Cost of Goods Sold for the three months ended in Dec. 2024 was kr0.00 Mil.

The historical rank and industry rank for Lipum AB's Days Payable or its related term are showing as below:

OSTO:LIPUM's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 116.05
* Ranked among companies with meaningful Days Payable only.

Lipum AB's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00). stayed the same

Lipum AB Days Payable Historical Data

The historical data trend for Lipum AB's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Days Payable Chart

Lipum AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

Lipum AB Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Lipum AB's Days Payable

For the Biotechnology subindustry, Lipum AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lipum AB's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Days Payable distribution charts can be found below:

* The bar in red indicates where Lipum AB's Days Payable falls into.

Save Embed

;

Save Embed

;

Lipum AB Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Lipum AB's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (4.1	+	7.69)	/	2 )	/	0	*	365
=	5.895					/	0	*	365
=	N/A

Lipum AB's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (3.906	+	7.69)	/	2 )	/	0	*	365 / 4
=	5.798					/	0	*	365 / 4
=	N/A

Lipum AB Days Payable Related Terms

Thank you for viewing the detailed overview of Lipum AB's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Lipum AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tvistevagen 48 C, Umea, SWE, 907 36

Website

https://www.lipum.se

Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB Headlines

No Headlines